EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders

Al-Hassan Soliman Wadan, Mostafa K Abd El-Aziz, Doha El-Sayed Ellakwa

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-10 · 398 (10) · 13397-13426

DOI: 10.1007/s00210-025-04155-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 05.05.2025. Verfasst von Al-Hassan Soliman Wadan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oral Biology Department, Faculty of Dentistry, Galala University (15888), Galala Plateau, Attaka, Suez Governorate, Egypt. Alhassan.soliman.168@gmail…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Mental Disorders, Gastrointestinal Diseases, Nervous System Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modulation of gut microbiota presents promising therapeutic possibilities for various health conditions, ranging from gastrointestinal infections to neurodegenerative and mental health disorders. Among the available interventions, gut microbiota modulators (GMMs) such as probiotics and prebiotics have demonstrated significant potential in infection prevention and neuroprotection. Despite these encouraging findings, the clinical application of GMMs remains challenging due to safety concerns and inconsistent effectiveness across diverse patient populations. These factors create substantial barriers to the widespread adoption of microbiota-based therapies in clinical practice. To overcome these challenges and fully leverage the therapeutic potential of microbiota modulation, this review explores the feasibility of repurposing GMMs for managing multiple health disorders. A broad spectrum of microbiota-targeted strategies is examined, including dietary modifications, fecal microbiota transplantation, bacteriophage therapy, microbiome engineering, and immune system modulation. A particularly innovative approach involves integrating GMMs with pharmaceutical delivery systems to enhance therapeutic efficacy while mitigating potential adverse effects. This integrative strategy underscores the pivotal role of the gut microbiome in health and disease, supporting the development of precision medicine tailored to individual patient needs. By combining GMMs with targeted delivery mechanisms, this approach not only improves treatment effectiveness but also addresses critical concerns regarding safety and patient variability. Furthermore, this review outlines future research directions within the rapidly evolving field of microbiota modulation, emphasizing the necessity of comprehensive clinical trials and long-term safety evaluations. By critically assessing both the challenges and opportunities associated with microbiota-based interventions, this study provides a strategic framework for translating experimental research into viable clinical applications. A holistic approach to gut microbiota modulation has the potential to redefine treatment paradigms, offering personalized therapeutic strategies for a wide range of disorders and advancing the broader field of precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMental DisordersGastrointestinal DiseasesNervous System DiseasesBrainBrain-Gut AxisHumansAnimalsProbioticsPrebioticsFecal Microbiota Transplantation

Stichwörter der Autor:innen

Drug repurposingFecal transplantation (FMT)Gut microbiota modulatorsMicrobiota-gut-brain axisPrebioticsProbiotics

Substanzen

Prebiotics

Autor:innen und Institutionen

  • Oral Biology Department, Faculty of Dentistry, Galala University (15888), Galala Plateau, Attaka, Suez Governorate, Egypt. Alhassan.soliman.168@gmail.com.
  • Faculty of Pharmacy, King Salman International University, Ras-Sudr, South Sinai, Egypt.
  • Clinical Pharmacology and Pharmacogenomics Research Group (CPPRG), Faculty of Pharmacy and Biotechnology, German University in Cairo-GUC, Cairo, Egypt.
  • Department of Biochemistry and Molecular Biology, Faculty of Pharmacy for Girls, Al-Azhar University, Cairo, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Sinai University, Kantra Branch, Ismailia, Egypt.

Förderung

  • Galala University

Zitieren

APA

Wadan, A. S., El-Aziz, M. K. A., & Ellakwa, D. E. (2025). The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(10), 13397-13426. https://doi.org/10.1007/s00210-025-04155-2

Vancouver

Wadan AS, El-Aziz MKA, Ellakwa DE. The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(10):13397-13426. doi:10.1007/s00210-025-04155-2

BibTeX
@article{Wadan2025,
  author = {Wadan, Al-Hassan Soliman and El-Aziz, Mostafa K Abd and Ellakwa, Doha El-Sayed},
  title = {The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {10},
  pages = {13397--13426},
  doi = {10.1007/s00210-025-04155-2}
}
Kostenlos starten →